Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-4,232
Closed -$8.42K 6193
2025
Q2
$8.42K Sell
4,232
-19,810
-82% -$36.2K ﹤0.01% 5215
2025
Q1
$34.9K Sell
24,042
-1,034
-4% -$1.91K ﹤0.01% 4976
2024
Q4
$51.9K Buy
25,076
+1,605
+7% +$3.01K ﹤0.01% 5078
2024
Q3
$41.3K Buy
23,471
+16,438
+234% +$42.2K ﹤0.01% 5061
2024
Q2
$102K Buy
7,033
+2,255
+47% +$31K ﹤0.01% 4201
2024
Q1
$79.5K Buy
4,778
+1,001
+27% +$16K ﹤0.01% 4396
2023
Q4
$60.6K Buy
3,777
+3,183
+536% +$42.3K ﹤0.01% 4433
2023
Q3
$7.99K Sell
594
-6,640
-92% -$93.5K ﹤0.01% 4600
2023
Q2
$124K Buy
7,234
+6,608
+1,056% +$102K ﹤0.01% 4138
2023
Q1
$10.3K Sell
626
-193
-24% -$3.09K ﹤0.01% 4715
2022
Q4
$13.7K Buy
819
+621
+314% +$11.2K ﹤0.01% 4729
2022
Q3
$3K Sell
198
-597
-75% -$8.68K ﹤0.01% 5384
2022
Q2
$9K Buy
+795
New +$9.44K ﹤0.01% 5402

Citigroup's HLVX Position: Q3 2025 in Review

Citigroup sold out of HilleVax (HLVX) in Q3 2025, closing a stake of 4,232 shares — an estimated $8.42K sold.

Citigroup first reported a position in HLVX in Q2 2022 and held it in 13 quarters. The position peaked at $124K in Q2 2023. 1 fund tracked by Wall St. Rank holds HLVX as of Q3 2025.

  • Citigroup reported no remaining HilleVax position as of Q3 2025 after selling out during the quarter.
  • Citigroup sold 4,232 HilleVax shares in Q3 2025, an estimated $8.42K.
  • Citigroup first reported a position in HilleVax in Q2 2022 and held it in 13 quarters.
  • Citigroup's HilleVax position peaked at $124K in Q2 2023.
  • 1 fund tracked by Wall St. Rank held HilleVax as of Q3 2025.

Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.